#Tyme stock price today registration#
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: or by telephone: (646) 975-6996. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC's website at or by contacting H.C. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. 333-245033) filed with the Securities and Exchange Commission (" SEC") on Augand declared effective on September 2, 2020.
The shares of common stock described above are being offered pursuant to a "shelf" registration statement (File No. TYME may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date of this communication. TYME intends to use the net proceeds from the offering for the development of the company's clinical and preclinical assets and for general corporate purposes, capital expenditures, working capital and general and administrative expenses. The gross proceeds of the offering are expected to be $100 million, prior to deducting placement agent's fees and other offering expenses payable by TYME. is acting as the exclusive placement agent for the offering. The offering is expected to close on or about February 8, 2021, subject to the satisfaction of customary closing conditions. TYME, an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq Rules.
0 kommentar(er)
